Francis Collins, director of the U.S. NIH, said in a public forum that his agency is "really bullish" about precision medicine. Precision medicine requires mounds of data to be viable; however, the necessary data may soon be available. Collins said the NIH's All of Us research program has drawn the interest of more than 300,000 willing participants to date, adding that the target enrollment of 1 million should be accomplished before the end of 2022.

Francis Collins, director of the U.S. NIH, said in a public forum that the agency is "really bullish" about precision medicine. However, while precision medicine requires mounds of data, which soon may be available, Collins said the NIH All of Us research program has drawn the interest of more than 300,000 willing participants to date, adding that the target enrollment of 1 million should be accomplished before the end of 2022.

SAO PAULO, Brazil – Latin America is following the lead of other developed markets by ramping up its focus on personalized medicine, but there are challenges, including the higher costs of those medicines and a lack of regulations.

Despite the arrival of FDA-approved tissue-agnostic targeted cancer therapies, there is increasing recognition that the response of tumors that are driven by the same oncogene differs according to their location.